{ "schemaVersion": 1, "organisationId": "O-678c9145b5b24f999f246b7b5ce0efa3", "slug": "resmed", "name": "RESMED INC", "updatedAt": "2026-09-28T12:30:22.04075Z", "sections": [ { "type": "OVERVIEW", "text": "ResMed Inc. is a San Diego-based medical technology company focused on sleep and breathing health and care delivered in residential settings. Its products include CPAP and other breathing-therapy devices, masks, ventilators and related digital health tools for people with sleep apnea, COPD and other respiratory conditions. It also provides software used by residential-care providers. Formed in 1989, the company’s early business centered on commercializing CPAP treatment for obstructive sleep apnea. [P68582197][P70123458][P75363859]\n\nResMed’s stated vision is to help people reach their full potential through better sleep and breathing, with care delivered at home. It operates internationally, with revenue reported across the Americas, Europe, Asia and other markets. For its fiscal year ended June 30, 2025, ResMed reported approximately $5.15 billion in revenue and employed approximately 10,600 people. [P38668392][T6355292][P8433919][P109982668]\n[P68582197][P70123458][P75363859][P38668392][T6355292][T6355292][P8433919][P109982668]", "updatedAt": "2026-09-28T12:30:22.04075Z" }, { "type": "PRODUCTS", "text": "ResMed’s sleep-apnea products include AirSense 11 CPAP and auto-adjusting PAP machines, AirCurve 11 bilevel machines, and the portable AirMini CPAP. AirSense 11 offers an integrated humidifier, sleep-onset detection and connected patient-support features; AirCurve 11 provides bilevel pressure support, with modes for obstructive or central sleep apnea depending on the model. AirMini uses waterless humidification. ResMed also sells nasal, nasal-pillow and full-face masks under the AirFit and AirTouch lines, along with diagnostic products and therapy accessories. [P43368228][P62018696][https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm]\n\nIts respiratory-care range includes Astral and Stellar ventilators for invasive or non-invasive support and Lumis non-invasive ventilation devices. AirView enables clinicians and equipment providers to monitor therapy remotely and manage device settings, while the myAir app gives patients therapy information, guidance and troubleshooting support. [P151142][P80356882] ResMed’s residential-care software includes Brightree for home medical equipment and related providers, MatrixCare for long-term and post-acute care, and MEDIFOX DAN for care providers in Germany. [P106111692]\n\nIn fiscal 2025, Sleep and Breathing Health generated about 87.5% of ResMed’s revenue, while Residential Care Software accounted for approximately 12%. Masks, diagnostic products and accessories *together* represented approximately 36% of revenue; ResMed did not report a separate mask-only percentage. [P56863149][P8433919][P104568916][P90819194]\n[P43368228][P62018696][P151142][P80356882][P106111692][P56863149][P8433919][P104568916][P90819194][https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm]", "updatedAt": "2026-09-28T12:30:22.04075Z" }, { "type": "GEOGRAPHY", "text": "ResMed is headquartered in San Diego, California, and operates across the Americas, Europe, Asia and Australia. Its principal Sydney site houses research and development, offices and manufacturing facilities. Manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. [P68582197][P108582287]\n\nIn fiscal 2025, Sleep and Breathing Health revenue was $3.00 billion in the United States, Canada and Latin America—about 66.5% of that business’s revenue—and $1.51 billion in Europe, Asia and other markets, about 33.5%. These figures exclude Residential Care Software revenue, which is not allocated by geography in the regional breakdown. [T6355292] As of June 30, 2025, ResMed had approximately 10,600 employees: 31% in the United States, Canada and Latin America; 31% in Asia; 14% in Australia; and 24% in Europe. [P109982668]\n[P68582197][P108582287][T6355292][T6355292][T6355292][P109982668]", "updatedAt": "2026-09-28T12:30:22.04075Z" }, { "type": "SEGMENTS", "text": "ResMed reports two operating segments. **Sleep and Breathing Health** comprises medical devices and related solutions for sleep and respiratory disorders, including positive airway pressure and ventilation devices, masks, diagnostics and connected-care tools. It generated approximately 87.5% of revenue in fiscal 2025. **Residential Care Software** supplies cloud-based business-management and care software to providers such as home medical equipment suppliers, home health and hospice organizations, skilled nursing facilities and senior living operators. It generated approximately 12.5% of revenue. [P13818905][P92407995][T10553810]\n\nThe company renamed these segments in fiscal 2025 from “Sleep and Respiratory Care” and “Software as a Service,” respectively, without changing how segment financial information is prepared. As a separate product-mix measure—not an additional segment—masks, diagnostic products and accessories accounted for approximately 36% of total fiscal 2025 revenue. [P13818905][P90819194]\n[P13818905][P92407995][T10553810][T10553810][T10553810][P90819194]", "updatedAt": "2026-09-28T12:30:22.04075Z" }, { "type": "HISTORY", "text": "ResMed’s origins trace to continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea, first used by Dr. Colin Sullivan in 1980. After Baxter acquired rights to the technology, Dr. Peter Farrell established ResMed’s Australian subsidiary in 1989 to acquire those rights and Baxter’s CPAP-device business. ResMed introduced its first CPAP device that year. ResMed Inc. was formed as a Delaware holding company in 1994 and completed its initial public offering in 1995; its shares moved to the New York Stock Exchange in 1999. [P99392119][P85166255][P70123458][P61389347][P76684867]\n\nResMed expanded its respiratory-device range over subsequent decades, releasing the AirSense 10 platform during fiscal 2015 and the portable AirMini CPAP in 2017. Michael J. Farrell had succeeded Peter Farrell as chief executive by 2013. [P66265873][P111450857][P18154450]\n\nThe company also expanded into software for care delivered outside hospitals, acquiring Brightree in 2016 and MatrixCare in 2018. It began a controlled launch of its next-generation AirSense 11 platform in fiscal 2021 and announced an agreement to acquire German care-software provider MEDIFOX DAN in 2022. [P90758021][P118839422]\n[P99392119][P85166255][P70123458][P61389347][P76684867][P66265873][P111450857][P18154450][P90758021][P118839422]", "updatedAt": "2026-09-28T12:30:22.04075Z" } ], "sources": [ { "id": "P68582197", "href": "https://app.finbar.com/go?id=P68582197", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P70123458", "href": "https://app.finbar.com/go?id=P70123458", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P75363859", "href": "https://app.finbar.com/go?id=P75363859", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P38668392", "href": "https://app.finbar.com/go?id=P38668392", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "T6355292", "href": "https://app.finbar.com/go?id=T6355292", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P8433919", "href": "https://app.finbar.com/go?id=P8433919", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P109982668", "href": "https://app.finbar.com/go?id=P109982668", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P43368228", "href": "https://app.finbar.com/go?id=P43368228", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P62018696", "href": "https://app.finbar.com/go?id=P62018696", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm", "href": "https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm", "label": "www.sec.gov" }, { "id": "P151142", "href": "https://app.finbar.com/go?id=P151142", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P80356882", "href": "https://app.finbar.com/go?id=P80356882", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P106111692", "href": "https://app.finbar.com/go?id=P106111692", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P56863149", "href": "https://app.finbar.com/go?id=P56863149", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P104568916", "href": "https://app.finbar.com/go?id=P104568916", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P90819194", "href": "https://app.finbar.com/go?id=P90819194", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P108582287", "href": "https://app.finbar.com/go?id=P108582287", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P13818905", "href": "https://app.finbar.com/go?id=P13818905", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P92407995", "href": "https://app.finbar.com/go?id=P92407995", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "T10553810", "href": "https://app.finbar.com/go?id=T10553810", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P99392119", "href": "https://app.finbar.com/go?id=P99392119", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P85166255", "href": "https://app.finbar.com/go?id=P85166255", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P61389347", "href": "https://app.finbar.com/go?id=P61389347", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P76684867", "href": "https://app.finbar.com/go?id=P76684867", "label": "RESMED INC — Full financial report (2025 Y)", "documentId": "D-cc6adfd93aef46ec80ff2bfa0bd56024" }, { "id": "P66265873", "href": "https://app.finbar.com/go?id=P66265873", "label": "RESMED INC — Full financial report (2015 Y)", "documentId": "D-0fe65200e65f48d7b8629b8a6ad5c20f" }, { "id": "P111450857", "href": "https://app.finbar.com/go?id=P111450857", "label": "RESMED INC — Full financial report (2017 Y)", "documentId": "D-61435bbadbe143d58cb934b5863a1e9f" }, { "id": "P18154450", "href": "https://app.finbar.com/go?id=P18154450", "label": "RESMED INC — Full financial report (2013 Y)", "documentId": "D-a497cdcef26c40a2ab6e8c9403e2a7a3" }, { "id": "P90758021", "href": "https://app.finbar.com/go?id=P90758021", "label": "RESMED INC — Full financial report (2021 Y)", "documentId": "D-6efea7129b9e48ddbc71c9134e00e426" }, { "id": "P118839422", "href": "https://app.finbar.com/go?id=P118839422", "label": "RESMED INC — Press release (2022 Y)", "documentId": "D-efcc0f842a554643990a7654107bda9c" } ] }